Publication:
Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.

dc.contributor.authorMolina-Ortega, A
dc.contributor.authorMartin-Gandul, C
dc.contributor.authorMena-Romo, J D
dc.contributor.authorRodriguez-Hernandez, M J
dc.contributor.authorSuñer, M
dc.contributor.authorBernal, C
dc.contributor.authorSanchez, M
dc.contributor.authorSanchez-Cespedes, J
dc.contributor.authorPerez Romero, P
dc.contributor.authorCordero, E
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases
dc.date.accessioned2023-01-25T10:22:54Z
dc.date.available2023-01-25T10:22:54Z
dc.date.issued2018-10-05
dc.description.abstractAlthough solid organ transplant (SOT) recipients with pretransplant serology for cytomegalovirus (CMV-R+) are considered at intermediate risk for CMV infection post transplantation, CMV infection remains a major cause of morbidity in this population. We prospectively characterized whether having pretransplant CMV-specific cellular immunity is independently associated with controlling infection after transplantation in R + SOT recipients. A prospective cohort of consecutive R + SOT recipients that received pre-emptive treatment for CMV infection was monitored after transplantation and variables were recorded during the follow-up. The cytomegalovirus-specific T-cell immune response was characterized by intracellular cytokine staining and viral loads determined using real-time PCR. One hundred and thirty-five R + SOT recipients were included (67 kidney, 64 liver, four liver-kidney). Only one-third of the patients (42; 31.85%) had CMV-specific T-cell immunity (CD8+CD69+INF-γ+ T cells >0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p 0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p  Our results show that having a pretransplant CMV specific T-cell response may be associated with a lower rate of CMV viraemia and less antiviral treatment after transplantation; however, more prospective studies are needed to confirm these findings.
dc.description.versionSi
dc.identifier.citationMolina-Ortega A, Martín-Gandul C, Mena-Romo JD, Rodríguez-Hernández MJ, Suñer M, Bernal C, et al. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect. 2019 Jun;25(6):753-758.
dc.identifier.doi10.1016/j.cmi.2018.09.019
dc.identifier.essn1469-0691
dc.identifier.pmid30292792
dc.identifier.unpaywallURLhttp://www.clinicalmicrobiologyandinfection.com/article/S1198743X18306578/pdf
dc.identifier.urihttp://hdl.handle.net/10668/13037
dc.issue.number6
dc.journal.titleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
dc.journal.titleabbreviationClin Microbiol Infect
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number753-758
dc.provenanceRealizada la curación de contenido 18/02/2025
dc.publisherElsevier Ltd
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.relation.projectIDPI11-02800
dc.relation.projectIDPI11-01357
dc.relation.projectIDPI14-00165
dc.relation.projectIDREIPI RD12/0015/0001
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S1198-743X(18)30657-8
dc.rights.accessRightsRestricted Access
dc.subjectCMV
dc.subjectCMV-specific immune response
dc.subjectCytomegalovirus infection
dc.subjectReplication episodes
dc.subjectSerological status
dc.subjectSolid organ transplantation
dc.subject.decsInmunidad
dc.subject.decsInfecciones
dc.subject.decsTrasplante
dc.subject.decsTerapéutica
dc.subject.decsLinfocitos T
dc.subject.decsAntivirales
dc.subject.decsPacientes
dc.subject.decsCitomegalovirus
dc.subject.decsHígado
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCytokines
dc.subject.meshCytomegalovirus
dc.subject.meshCytomegalovirus Infections
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOrgan Transplantation
dc.subject.meshProspective Studies
dc.subject.meshStaining and Labeling
dc.subject.meshT-Lymphocytes
dc.subject.meshViral Load
dc.subject.meshYoung Adult
dc.titleImpact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number25
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format